Angiogenesis and tumor metastasis.
暂无分享,去创建一个
[1] E. Unanue,et al. Activated macrophages induce vascular proliferation , 1977, Nature.
[2] J. Folkman. Clinical Applications of Research on Angiogenesis , 1995 .
[3] S. Fox,et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.
[4] R. Khokha. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. , 1994, Journal of the National Cancer Institute.
[5] H. Koeppen,et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. , 1988, Cancer research.
[6] Erwin G. Van Meir,et al. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.
[7] A. Chella,et al. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (Stage IIIA‐N2): Impact of adjuvant therapies in a subset of patients at high risk of recurrence , 1996, Cancer.
[8] J. Folkman,et al. Protamine is an inhibitor of angiogenesis , 1982, Nature.
[9] Tumor angiogenesis in human lung adenocarcinoma , 1994 .
[10] E. Kohn,et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. , 1996, Cancer research.
[11] W. Gradishar,et al. Clinical trials of antiangiogenic agents , 1997, Current opinion in oncology.
[12] B. Zetter,et al. Inhibition of cell motility by interferon. , 1980, Science.
[13] R. Steiner. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. , 1992, EXS.
[14] Y. DeClerck,et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. , 1994, Cancer research.
[15] M. Brawer,et al. Quantitative microvessel density: A staging and prognostic marker for human prostatic carcinoma , 1996, Cancer.
[16] J. Folkman,et al. Angiogenic factors. , 1987, Science.
[17] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[18] R. Hoffman,et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. , 1994, Cancer research.
[19] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] E. Reed,et al. The Pharmacokinetics of TNP‐470, a New Angiogenesis Inhibitor , 1997, Pharmacotherapy.
[21] Lucio Luzzatto,et al. Somatic Mutations in Paroxysmal Nocturnal Hemoglobinuria: A Blessing in Disguise? , 1997, Cell.
[22] R. Khokha,et al. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. , 1996, Oncogene.
[23] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Bagavandoss,et al. Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.
[25] P. Gullino,et al. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. , 1975, Cancer research.
[26] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[27] R. Langer,et al. Angiogenesis capacity as a diagnostic marker for human eye tumors. , 1979, Surgery.
[28] C. Bucana,et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Richie,et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.
[30] T. Maione,et al. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. , 1995, Journal of the National Cancer Institute.
[31] N. Weidner,et al. Angiogenesis in breast cancer. , 1996, Cancer treatment and research.
[32] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[33] J. Folkman,et al. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.
[34] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[35] S. Orlow,et al. Supraumbilical Midabdominal Raphe, Sternal Atresia, and Hemangioma in an Infant: Response of Hemangioma to Laser and Interferon Alfa‐2a , 1993, Pediatric dermatology.
[36] B. Teicher,et al. Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents , 1994, International journal of cancer.
[37] D. Cheresh,et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.
[38] S. Soker,et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.
[39] T. Morris,et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. , 1995, Cancer research.
[40] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[41] S. Szabó,et al. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. , 1985, Science.
[42] R. Auerbach,et al. Angiogenesis inhibition: a review. , 1994, Pharmacology & therapeutics.
[43] D. Ingber,et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.
[44] P. Steeg,et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. , 1994, Cancer research.
[45] E. Sage,et al. Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. , 1996, Seminars in cancer biology.
[46] M. Stack,et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. , 1996, Cancer research.
[47] H. Dvorak,et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. , 1993, Cancer research.
[48] B. Zetter,et al. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells. , 1981, The New England journal of medicine.
[49] Y. DeClerck,et al. Protease inhibitors: role and potential therapeutic use in human cancer. , 1994 .
[50] M A Moses,et al. Identification of an inhibitor of neovascularization from cartilage. , 1990, Science.
[51] J. Folkman,et al. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. , 1984, Science.
[52] S. Groshen,et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.
[53] J. Martial,et al. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. , 1993, Endocrinology.
[54] E. Borden,et al. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.
[55] W. T. Chen,et al. Proteases associated with invadopodia, and their role in degradation of extracellular matrix. , 1996, Enzyme & protein.
[56] W. Stetler-Stevenson,et al. Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation , 1993, Journal of cellular physiology.
[57] N. Weidner,et al. Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.
[58] S. Steinberg,et al. Tumor angiogenesis in advanced stage ovarian carcinoma. , 1995, The American journal of pathology.
[59] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[60] J. Folkman,et al. Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors , 1972, Annals of surgery.
[61] Tatsuo Tanaka,et al. Comparison of the inhibitory effect of the angiogenesis inhibitor, TNP‐470, and mitomycin c on the growth and liver metastasis of human colon cancer , 1995, International journal of cancer.
[62] J. Mulliken,et al. Interferon alfa‐2a therapy for life‐threatening hemangiomas of infancy , 1992, The New England journal of medicine.
[63] S. Eccles,et al. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). , 1996, Cancer research.
[64] A. Harris,et al. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] 山崎 浩一. Tumor angiogenesis in human lung adenocarcinoma , 1995 .
[66] G. Sledge,et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.
[67] E. Scanziani,et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. , 1995, Journal of the National Cancer Institute.
[68] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[69] J. Folkman. Tumor angiogenesis. , 1985, Advances in cancer research.
[70] D. Fernig,et al. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. , 1994, Progress in growth factor research.
[71] Mark D. Johnson,et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase , 1994, Journal of cellular physiology.
[72] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[73] C. Juttner,et al. Blood cell transplantation , 1995, Current opinion in oncology.
[74] G. Healy,et al. Interferon Alfa-2A Therapy for Airway Hemangiomas , 1994, The Annals of otology, rhinology, and laryngology.
[75] B. Teicher,et al. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.
[76] J. Singh,et al. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[77] R. D'Amato,et al. Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[78] C. Cordon-Cardo,et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. , 1993, Journal of the National Cancer Institute.
[79] H. Krutzsch,et al. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin‐binding domain and synthetic peptides from the type I repeats of thrombospondin , 1993, Journal of cellular biochemistry.
[80] E. Sage,et al. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.
[81] D L Wiggins,et al. Tumor angiogenesis as a prognostic factor in cervical carcinoma. , 1995, Gynecologic oncology.
[82] N. Ferrara,et al. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. , 1991, Endocrinology.
[83] Y. Chung,et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] D. Hanahan,et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[85] M. Toi,et al. Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.
[86] K. Dameron,et al. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.
[87] Peter J. Polverini,et al. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene , 1989, Cell.
[88] B. Zetter,et al. Mast cells and angiogenesis. , 1992, Seminars in cancer biology.
[89] M. Iruela-Arispe,et al. Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[90] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[91] B. Hennig,et al. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. , 1996, Anticancer research.
[92] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[93] R. Auerbach,et al. Lymphocyte-induced angiogenesis in tumor-bearing mice , 1976, Science.
[94] J. Folkman,et al. Fighting cancer by attacking its blood supply. , 1996, Scientific American.
[95] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[96] H. Shimada,et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. , 1992, Cancer research.
[97] R. Steele,et al. Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. , 1996, British Journal of Cancer.
[98] D. Benezra. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.
[99] A. Uchida,et al. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP‐470 in murine osteosarcoma , 1995, International journal of cancer.
[100] O. Volpert,et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity , 1993, The Journal of cell biology.
[101] L. Dehner,et al. TREATMENT OF HAEMANGIOENDOTHELIOMAS WITH ALPHA INTERFERON , 1989, The Lancet.
[102] C. Fombrun,et al. Matrix , 1979, Encyclopedic Dictionary of Archaeology.
[103] R. D'Amato,et al. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470 , 1997, Nature Medicine.
[104] L. Davel,et al. Lymphocyte-induced angiogenesis: correlation with the metastatic incidence of two murine mammary adenocarcinomas. , 1986, Invasion & metastasis.
[105] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[106] L. Ellis,et al. Angiogenesis and breast cancer metastasis , 1995, The Lancet.
[107] L. Matrisian,et al. Complex roles of matrix metalloproteinases in tumor progression. , 1996, Current topics in microbiology and immunology.